Geode Capital Management LLC Boosts Holdings in Vera Therapeutics, Inc. $VERA

Posted by Brian Himes on Jun 9th, 2026

Geode Capital Management LLC increased its stake in shares of Vera Therapeutics, Inc. (NASDAQ:VERA – Free Report) by 9.3% in the fourth quarter, according to its most recent Form 13F filing with the SEC. The fund owned 1,444,925 shares of the company’s stock after buying an additional 123,350 shares during the period. Geode Capital Management LLC’s holdings in Vera Therapeutics were worth $73,185,000 as of its most recent SEC filing.

A number of other large investors have also added to or reduced their stakes in VERA. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. increased its holdings in Vera Therapeutics by 7.7% during the first quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 30,905 shares of the company’s stock worth $753,000 after buying an additional 2,210 shares during the last quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its holdings in Vera Therapeutics by 22.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 98,013 shares of the company’s stock worth $2,354,000 after buying an additional 17,907 shares during the last quarter. Jane Street Group LLC increased its holdings in Vera Therapeutics by 297.1% during the first quarter. Jane Street Group LLC now owns 41,578 shares of the company’s stock worth $999,000 after buying an additional 62,678 shares during the last quarter. JPMorgan Chase & Co. increased its stake in shares of Vera Therapeutics by 550.5% in the second quarter. JPMorgan Chase & Co. now owns 310,547 shares of the company’s stock worth $7,316,000 after purchasing an additional 262,805 shares in the last quarter. Finally, Legal & General Group Plc increased its stake in shares of Vera Therapeutics by 1.7% in the second quarter. Legal & General Group Plc now owns 50,418 shares of the company’s stock worth $1,188,000 after purchasing an additional 825 shares in the last quarter. Hedge funds and other institutional investors own 99.21% of the company’s stock.

Vera Therapeutics Trading Down 1.7%

Shares of VERA opened at $31.75 on Tuesday. The firm has a market cap of $2.28 billion, a price-to-earnings ratio of -5.73 and a beta of 0.93. The company has a debt-to-equity ratio of 0.15, a quick ratio of 13.64 and a current ratio of 13.64. Vera Therapeutics, Inc. has a fifty-two week low of $19.07 and a fifty-two week high of $56.05. The firm has a 50 day moving average price of $37.54 and a 200-day moving average price of $41.35.

Vera Therapeutics (NASDAQ:VERA – Get Free Report) last announced its quarterly earnings data on Thursday, May 7th. The company reported ($1.69) earnings per share for the quarter, missing analysts’ consensus estimates of ($1.33) by ($0.36). During the same period in the previous year, the company posted ($0.81) EPS. As a group, equities research analysts forecast that Vera Therapeutics, Inc. will post -6.23 earnings per share for the current year.

Insider Buying and Selling at Vera Therapeutics

In related news, CEO Marshall Fordyce sold 18,500 shares of Vera Therapeutics stock in a transaction on Tuesday, May 12th. The shares were sold at an average price of $36.74, for a total value of $679,690.00. Following the transaction, the chief executive officer directly owned 216,744 shares of the company’s stock, valued at $7,963,174.56. The trade was a 7.86% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 15.90% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts have recently weighed in on VERA shares. The Goldman Sachs Group reiterated a “buy” rating and issued a $90.00 target price on shares of Vera Therapeutics in a research note on Tuesday, June 2nd. TD Cowen restated a “buy” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Evercore set a $91.00 price objective on shares of Vera Therapeutics in a research report on Friday, May 15th. William Blair restated an “outperform” rating on shares of Vera Therapeutics in a research report on Tuesday, June 2nd. Finally, HC Wainwright raised their price objective on shares of Vera Therapeutics from $90.00 to $110.00 and gave the company a “buy” rating in a research report on Monday, March 2nd. Ten investment analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Vera Therapeutics has an average rating of “Moderate Buy” and a consensus target price of $78.00.

View Our Latest Stock Analysis on VERA

Vera Therapeutics Profile

(Free Report)

Vera Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies that harness the body’s own regulatory T cells to treat autoimmune and inflammatory diseases. By leveraging a proprietary protein engineering platform, the company designs Treg-selective cytokine variants intended to restore immune balance and provide targeted, disease-modifying effects. Its pipeline comprises multiple preclinical and clinical candidates aimed at indications characterized by chronic inflammation and autoimmunity.

Founded in 2018 and headquartered in Cambridge, Massachusetts, Vera Therapeutics collaborates with leading academic and research institutions to advance its development programs.